• search
Pharmaceutical Microbiology Testing Pharmaceutical Microbiology Testing

Pharmaceutical Microbiology Testing

We offer pharmaceutical microbiology testing services with a wide range of in vitro assays and infectious models that can be tailored as per customer requirements.

The pharmaceutical microbiology testing service at Aurigene is supported by BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has collaborated on numerous anti-bacterial and anti-fungal agent discovery projects with innovator pharma companies. We have a dedicated team of scientists and allied staff with vast experience in anti-infective drug discovery projects. We have established in vitro assays and in vivo murine efficacy models.

We also support generic product filings through bioequivalance studies of in vitro time-kill kinetics against reference drug.

Speak to our experts

Assay Capabilities:

In vitro pharmaceutical microbiology testing services

  • Pharmacodynamic studies:   Drug-organism interaction.
  • MIC and MBC:   Susceptibility indicators; major parameters used to quantify the activity of an antibacterial agent against the target pathogen
  • Time kill kinetics:   Information on the time course and rate of antimicrobial activity
  • PAE and PA-SME:   Information on persistent effects of antibacterial agents
  • Others:   Antimicrobial combination/effect of serum proteins on MIC/ biofilm studies

In vivo pharmaceutical microbiology testing services

  • Systemic infection models:   Acute lethal model to generate POC and determine ED50 - primary screening
  • Respiratory tract infection models:   Test efficacy of NCEs in highly vascularized tissue like lungs
  • Thigh infection models:   Test efficacy of NCEs in poorly vascularized tissues like thighs
  • Urinary tract infection models:   Testability of NCEs to clear UTIs
  • Organ burden models:   Testability of NCEs to clear the disseminated infection

Why Aurigene Pharmaceutical Microbiology Testing Services?

Submissions to the US FDA

Highly qualified & experienced scientists

Audited by the US FDA with Zero 483 in 2019

BSL-2 compliant microbiology lab

Wide range of infectious models & microbiology assay capabilities

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

PROTACs: Research for a life without cancer

OCTOBER 01, 2024

PROTACs: Research for a life without cancer

PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...

Read More

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

Read More

Case study: Tackling CYP 2C9 inhibition challenges

The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...

Read More

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

2022

Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack